Volition announces groundbreaking lateral flow test for point-of-care quantification of nucleosomes

Henderson, nev. , july 8, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device.
VNRX Ratings Summary
VNRX Quant Ranking